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Introduction: Kidney cancer accounted for 1. 8% of global cancer deaths
according to Globocan 2020 estimates, with most of these being renal cell
carcinomas. Lower rates of renal cell carcinoma are reported for Africa and
these are expected to change for a combination of reasons. The clinical and
morphologic characteristics of renal cell carcinoma seen within Kenya have
not been described before. This study aims to partially ﬁll this gap.
Materials and methods: This was a cross-sectional descriptive study
examining electronic histopathology reports from the Aga Khan University
Hospital Nairobi Laboratory for the period January 2016 to May 2022.
Results: Sixty cases of renal cell carcinoma were identiﬁed. The mean age
at diagnosis was 55.3 years. The most common histologic subtype diagnosed
was clear cell renal cell carcinoma (41.7%), followed by papillary renal cell
carcinoma and renal cell carcinoma not further speciﬁed (both 21.7%), and
chromophobe renal cell carcinoma (11.7%). The most frequent specimen type
was resection, followed by cores of renal masses. The mean tumor size was
8.5 cm. Sixty-seven percent of patients presented with Stage III and above.
Discussion: Renal masses were the commonest clinical indication for biopsy
among the records reviewed. The male to female ratio, as well as the mean
age at presentation were comparable to what is described in literature for
other regions of the world. The proportions of the commonest histologic
subtypes matched what is described in other parts of the world. Challenges
in the identiﬁcation of histologic subtypes included having a limited panel of
antibodies for diagnosis and the lack of genetic molecular tests for histotyping.
Conclusion: The spectrum of histologic subtypes of renal cell carcinoma seen
at a tertiary referral hospital in Nairobi, Kenya was similar to that described
in other parts of Africa and the globe. The age at presentation with renal
cell carcinoma was consistent with what has been described in literature.
Challenges were identiﬁed in the accurate histotyping of renal cell carcinoma
due to constrained resources. Majority of cases diagnosed presented at
advanced stage.
KEYWORDS
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Introduction

and male genital tumors includes entities that are defined by
molecular genetic abnormalities (9). This makes it challenging to
accurately diagnose these tumor entities because the necessary
molecular tests are not widely available, particularly so in lowand medium-income countries (LMICs).
The most common subtypes of RCC described include clear
cell (75–85% of all RCC), papillary (10–15%) and chromophobe
(5–10%). Of these, clear cell renal cell carcinoma tends to have
a worse prognosis than most of the other subtypes, and a more
aggressive clinical course. The other subtypes with bad prognosis
are equivalent to the prognosis of clear cell renal cell carcinoma.
Some of the rare histologic subtypes such as clear cell papillary
RCC, have indolent behavior and this is now categorized as a
tumor rather than carcinoma (9).
Management of renal cell carcinoma is dependent on the
histologic subtype and the stage at disease presentation, with
only surgery being curative for early and localized disease. There
are several approved targeted therapies that may also be used
in the adjuvant setting subsequently. Treatment of advanced
renal cell carcinoma is supportive, although many new targeted
treatments are under investigation (10, 11). Access to these
targeted therapies remains a challenge in LMICs due to the
prohibitive cost.
The Aga Khan University Hospital Nairobi Main Laboratory
is part of a private nonprofit institution, the Aga Khan University
Hospital. The anatomic pathology laboratory processes 14–
16,000 surgical specimens annually, covering all areas of
surgical pathology practice. The laboratory receives and reports
specimens from the parent hospital as well as several private,
faith-based and government institutions.
There is an epidemiological need to define the clinical and
morphologic characteristics of renal cell carcinoma seen within
Kenya specifically, and the East Africa region in general, as
these data do not exist to the best of our knowledge. This
clinicopathologic review aims to partially fill this gap. It is
hoped that this information will inform policy and guide the
allocation of resources such as training in oncology care, and the
development and refinement of treatment strategies.
We aimed to describe the clinical and pathologic
characteristics of renal cell carcinoma as seen at Aga Khan
University Hospital (AKUHN) from January 2016 to May 2022.
This description includes the presentation and diagnostic work
up where available and/or relevant.

Kidney cancer is the 14th most common cancer by incidence
and accounted for 1.8% of global deaths from cancer according
to Globocan 2020 estimates (1), with most of these cancers
being renal cell carcinomas (RCC). Globocan 2020 estimates
that kidney cancer represented 1.1% of new cancers and
1.1% of deaths from cancer in Kenya (2). Most early-stage
RCC are discovered on routine imaging for other diseases or
patient complaints. Less than 20% of patients present with
pressure (flank pain, abdominal fullness or swelling), urinary
tract symptoms (bleeding, repeated infections from obstruction)
or paraneoplastic syndromes (3). Of note, up to 20% of
patients may present initially with metastatic disease to various
sites (4, 5).
Risk factors for RCC include advancing age, male sex,
smoking, and obesity. The global age standardized incidence
rate for renal cancer per 100,000 is 6.1 for males and 3.2 for
females (1). Dietary risk factors such as vegetable or meat intake
have shown conflicting relationship with incidence of RCC in
various studies (3). Acquired cystic kidney disease in patients
on dialysis is also an established risk factor (6). Less commonly,
rare genetic syndromes are associated with RCC including von
Hippel-Lindau syndrome, Hereditary papillary renal carcinoma,
Birt-Hogg-Dube syndrome, Succinate dehydrogenase (SDH)–
deficiency, Hereditary leiomyomatosis and renal cell cancer and
Hereditary renal carcinoma (HRC).
The highest incidence of renal cell carcinoma has been
observed in Belarus and North America with lower rates
reported among populations in Africa (3, 7). These reportedly
lower rates are likely a reflection of disparities in access and
provision of allopathic healthcare. One of the consequences
of this is under-reporting because of inadequate infrastructure
that leads to underperformance of cancer registries (4).
Thus, this low incidence of RCC in Africa may represent
an underestimation. In multiracial populations, it has been
observed than individuals with African ancestry have an
increased risk for RCC and worse outcomes (7). The World
Health Organization (WHO) estimates that 1 in 5 adults and 1
in 10 children and teenagers will be obese by December 2023
in 10 high-burden African countries (8). There is already an
established link between being overweight and obese and the
risk for developing renal cell carcinoma. It is therefore expected
that this increase in the number of obese and overweight
individuals will lead to an increase in the incidence of RCC.
It is also possible that the incidence of RCC will increase in
sub-Saharan Africa, in the coming years, with increasing use of
radiologic imaging for various other conditions as this becomes
more available.
There are several distinct histologic subtypes of RCC that
have been described, with distinct clinical behavior including
presentation, aggressiveness, and response to targeted therapy
(9). In addition, the current WHO 2022 classification of urinary
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TABLE 1 Age at diagnosis of renal cell carcinoma.

Number of Youngest Oldest Mean Std. Deviation
patients

02

Males

33

21

85

60.7

16.9

Females

27

26

86

48.7

18.4

Combined

60

21

86

55.3

18.5
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Materials and methods

renal cell carcinomas diagnosed in that period were included
in the study. Data collected was entered in Microsoft Excel
2021 sheets. Data analysis was performed using Excel and SPSS
version 20. The most relevant study limitation was finding
incomplete reports.

This was a cross-sectional descriptive study examining
electronic histopathology reports from the Aga Khan University
Hospital Nairobi Main Laboratory for the study duration. All

FIGURE 1

Boxplot comparing the age at diagnosis of renal cell carcinoma for males, females and both combined.

FIGURE 2

Bar graph showing the histologic subtypes of renal cell carcinoma. CCRCC, Clear cell; RCC, Renal cell carcinoma not otherwise speciﬁed;
MTSC, Mucinous tubular and spindle cell.
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Results

TABLE 2 Tumor size for resection specimens (N = 32).

Records were available for 60 patients with a histopathologic
diagnosis of renal cell carcinoma, six of which were of biopsies
from metastatic sites.
The clinical presentation was recorded for 45 cases. The
commonest presentation of patients with RCC was a renal mass
in 29 patients (64%, 95% CI 49–78), followed by flank pain in 8
patients (18%, 95% CI 8–32) and hematuria in 3 patients (6%,
95% CI 2–18). Many patients had more than one presentation
recorded e.g., renal mass and hematuria and others had a single
unique presentation such as metastasis to a unique site.
RCC was diagnosed with slightly higher frequency in males
than females with a male to female ratio of 1.22:1.
The average and median age at diagnosis of RCC are
shown in Table 1 and compared in Figure 1. The mean age at
presentation with renal cell carcinoma was older for males by 12
years compared to females.
The most common histologic subtype diagnosed was clear
cell RCC. The next most frequent were papillary RCC and RCC
not otherwise specified, as shown in Figure 2. Only two of the
papillary RCCs were type 1, the rest being either type 2 or mixed
type 1 and 2.
Tumor size was available for 32 resection specimens as
shown in Table 2.
The status of the margins was available for 29 of the resection
specimens. Most (22 cases) had achieved clear margins. The
positive margins were Gerota fascial margin (4 cases), renal
vein (3 cases), renal sinus, perinephric fat, and parenchymal
margins (1 of each).
Data on specimen type, tumor laterality, histologic grade,
and stage of carcinomas are shown in Table 3. Only 3 cases had
lymph nodes removed for staging.
Twenty-seven of the cases had immunohistochemistry done
either for histotyping or to identify the primary in cases of
metastatic disease, based on clinical and imaging suspicion. The
characteristics of these tumors are shown in Table 4.
Three of the metastatic sites biopsied were liver, making
this the commonest site of metastasis that had been biopsied.
Other metastatic sites included a scapular mass, lung, and a
mesenteric nodule.

Largest

Mean

Median

95% CI

3.5

18

9.7

8.5

1.4

Tumor size (cm)

TABLE 3 Data on specimen type, tumor laterality, histologic grade,
and tumor stage.

Variable

Value

Number
(%, 95%CI)

Specimen type (N = 60)

Nephrectomy (Simple or

21 (35%, 23–48)

unspecified)

Laterality (N = 49)

Histologic grade (N = 39)

Stage (AJCC prognostic

Radical nephrectomy

13 (21.7%, 12–34)

Renal core

16 (26.7%, 16–40)

Partial nephrectomy

2 (3.3%, 0.4–12)

Other core

5 (8.3%, 2.8–18)

Other

3 (5%, 1–14)

Right

25

Left

24

1

10 (26%, 13–42)

2

18 (46%, 30–63)

3

5 (13%, 4–27)

4

6 (15%, 5–30)

I

9 (20%, 9–34)

II

6 (13%, 5–26)

III

14 (30%, 18–46)

groups) (N = 46)

IV (Locally advanced)

6 (13%, 5–26)

IV (Metastatic)

11 (24%, 13–39)

and therefore consistent with what is known that renal cell
carcinoma has a slight male preponderance (1).
The mean age at which renal cell carcinoma was diagnosed
was 55.3 years which is similar to what has been described in
literature. More than 77% of kidney cancer patients are aged
older than 50 years (12). The age also varied between men and
women with males presenting at a slightly older age group, again
similar to what has been described for global data (12).
The commonest histologic subtypes seen were similar in
proportion to what has been described in other parts of the world
and Africa in particular. It is noted that the current (2022) WHO
Classification does not recommend grouping of papillary RCC
into types 1 or 2, and the data presented represent the prior
historical classification. Table 5 shows data from other studies in
various parts of the African continent.
There were challenges in the diagnosis of RCC that
led to a proportion of tumors being categorized as RCC,
not otherwise specified. Although the available panel of
antibodies for immunohistochemistry was usually adequate
to make a diagnosis of renal cell carcinoma, it was sometimes

Discussion
A renal mass was the most common clinical presentation
recorded in the reports, it is possible that the renal mass was
found following investigation for the symptoms of abdominal
fullness, pain, or hematuria. This sequence of preoperative
clinical investigation was not necessarily captured in the request
form accompanying the specimens submitted for evaluation.
The ratio of males to females in our study population was
1.22:1, which is compares to the described global ratio of 1.58:1,
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Case

Diagnosis

Age

Sex

Specimen

Pathologic Stage

Positive IHC stains

Negative IHC stains

1

RCC

39

F

Scapular mass

M

AE1/AE3, Vimentin, EMA, E-cadherin

TTF1, HER2

2

Chromophobe

31

F

Nephrectomy

T2bNX

CK7

CD10, Vimentin, CD117, RCC, Inhibin

3

CCRCC

63

M

Mesenteric nodule

M

AE1/AE3, Vimentin, CD10

EMA, Desmin, S100, CD117

4

CCRCC

79

M

Renal core

CD10, Vimentin

5

Chromophobe

27

F

Radical nephrectomy

T1bNX

CK7, RCC

Vimentin, CD10

6

CCRCC

63

F

Renal core

CD10, Vimentin
TTF1, CK7

05

7

RCC

60

M

Lung core

M

CD10

8

RCC

60

F

Renal core

Vimentin

CK7

9

RCC

74

M

Renal core

CK7

Synaptophysin, RCC, CD10, Inhibin

10

Chromophobe

30

M

Radical nephrectomy

T1

CK7

11

Chromophobe

77

M

Renal core

CK7, CD117

Vimentin, CD10

12

Papillary

37

M

Renal core

CK7, AMACR, CD10

13

CCRCC

30

M

Nephrectomy

T1bNX

Vimentin

14

Papillary

45

M

Nephrectomy

T1bNX

CD10, AMACR, CK7

15

RCC

66

M

Renal core

CK7, EMA, Vimentin, CD10

CK20

16

MTSC

64

F

Nephrectomy

T2bNX

AE1/AE3, AMACR, CK7

CD10

17

Papillary

27

F

Renal core

M

AE1/AE3, AMACR, Vimentin

CK7, CD10

18

RCC

54

F

Liver core

M

CK7

CK20, Synaptophysin, HepPar1

19

RCC

85

M

Liver core

M

CK7, CD10,

HepPar1, p63

20

CCRCC

26

F

Nephrectomy

T3aNX

AE1/AE3, CK7, CD10, Vimentin

WT1, S100

21

RCC

42

M

Renal core

M

CD10, Vimentin, AMACR

CK7, CD117,

22

Chromophobe

65

F

Renal core

CK7, CD10

Vimentin

23

CCRCC

54

F

Nephrectomy

T1a

AMACR, Vimentin, CD10, weak AE1/AE3

24

Papillary

79

M

Renal core

AE1/AE3, CK7, Vimentin, AMACR

S100

25

Chromophobe

84

M

Radical nephrectomy

T3aN0

CK7, CD117

26

MTSC

48

M

Radical nephrectomy

T3aNX

CK7, AMACR

27

Papillary

61

M

Renal core

CK7, Vimentin

S100, CD117

Vimentin

CK7, CD10, RCC

CK7

Vimentin
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CCRCC, Clear cell renal cell carcinoma; RCC, Renal cell carcinoma, not otherwise specified; MTSC, Mucinous tubular and spindle cell RCC.
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TABLE 4 Clinicopathologic characteristics and immunoproﬁle of renal cell carcinomas.
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TABLE 5 Renal cell carcinoma clinicopathologic features in studies from Africa.

References

Study
type

Year

Location

Amenu et al. (13)

Retrospective

2020

Ethiopia

Atanda et al. (14)

Systematic

2017

2020

Number
of cases

Age
(years)

Commonest RCC (%)

Pathologic
Stage ≥3

64

Median 53.4

CCRCC 55, ChRCC 20, PRCC 18

34%

Nigeria

443

Mean 45 ± 4

CCRCC 60–85.7, PRCC 23.8–46.2

80–96%

South Africa

31

Mean 56.39

CCRCC 74, PRCC T2 16, PRCC Mixed

(SD 10.16)

3, ChRCC 7

review
Du Plessis et. al (15)

Prospective
observational

Salako et al. (16)

Retrospective

2017

SW Nigeria

51

Median 41.7

CCRCC 60.8, ChRCC 17.6 PRCC13.7,

52.9%

Sarcomatoid 3.9, Mixed 1.9
CCRCC, Clear cell RCC; PRCC, Papillary RCC; ChRCC, Chromophobe RCC.

limited for histologic subtyping. The following antibodies
were not available: carbonic anhydrase IX, TFE3, SDHB
and TFEB. It should be noted that the latter three are
used to diagnose very rare histologic subtypes. On the
balance however, this may not always influence patient
care adversely given that surgical resection is the mainstay
of management for localized disease regardless of the
histologic subtype.
Additionally, the current WHO Classification has a category
of molecularly-defined RCC which cannot be diagnosed as
such without the use of ancillary molecular genetic testing.
Although in many instances there are morphologic clues
to suggest some of these entities (papillary morphology in
a young person and weak staining for keratin suggesting
MiT family translocation RCC, flocculent cytoplasm suggesting
SDH-deficient RCC), ultimately the definitive diagnosis requires
molecular genetic testing and the availability of this remains
a challenge. This becomes an area of potential future
collaboration and capacity building, both in the performance
and interpretation of molecular genetic testing. This capacity
would be useful in molecular oncopathology of tumors
from other sites as well, for diagnosis, prognosis and
even therapy.
The other challenge seen with histologic typing is the
changes in tumor morphology that would occur due to poor
fixation of a large tumor mass. Several of the nephrectomy
specimens were obtained from referring faith-based and
government health facilities which were not nearby. This meant
that some of the specimens had to be transported for several days
before they were processed. If the entire nephrectomy specimen
is placed in formalin without prior dissection, fixation may not
be optimal and partial autolysis in an already large vascularcompromised mass led to challenges in morphologic assessment
as well as immunohistochemical staining.
The surgical treatment was adequate in many cases, with
most of the resections having clear margins. The positive
margins were noted, as expected, in patients with advanced
stage disease, and probably represent the challenge of adequate

Frontiers in Medicine

resection with large tumor burden. Surgical resection is curative
treatment for early and localized disease in many instances and
this probably contributes to the overall low mortality of renal cell
carcinoma in that clinical context.
Thirty-four (57%) of the specimens on which a diagnosis of
renal cell carcinoma was made were complete resections of the
involved kidney, with only two of the specimens in our series
being partial nephrectomies. If as expected there is a future
increase in the diagnosis of smaller, earlier stage tumors, then
we may expect to see more partial nephrectomy specimens. The
other reason why there might be a possible change to more
partial nephrectomies is the fact that several of the risk factors for
RCC (chronic kidney disease, hypertension and obesity among
others) also compromise kidney function (17). This means that
there is greater need to perform nephron-sparing surgery as
much as possible which is also the approach recommended in
some current management guidelines (10).
The next most common specimen received was core biopsies
of renal masses, both from patients with disease limited to
the kidney as well as some patients with metastatic disease in
order to confirm the primary. This specimen type would also be
expected to increase in number, given the increasing role of renal
mass biopsy in the diagnosis of renal cell carcinoma. Renal mass
biopsy is increasingly being used to make decisions regarding
whether to pursue active surveillance or proceed with surgery
for localized renal masses suspicious for carcinoma (18).
Sixty-seven percent of the cases of RCC in our series were
diagnosed at advanced stage (Stage III and above). Although
this was similar to other data reported on the African continent
in Table 5, this proportion was much higher than that reported
in Euroamerica, for comparison, where only 25% of patients
present with advanced disease (19).

Conclusion
The spectrum of histologic subtypes of renal cell
carcinoma seen at a tertial referral hospital in Nairobi
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Kenya matched that described in other parts of Africa
and the globe. The age at presentation with renal cell
carcinoma was comparable to what has been described
in literature. A challenge was identified in the accurate
histotyping of renal cell carcinoma caused by lack of access
to molecular genetic testing. It is expected that there will
be an increase in the number of partial nephrectomies
and core biopsies received for diagnosis in order to plan
patient management.
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